The following materials provide detailed guidance on the administration of RYSTIGGO^® via subcutaneous infusion administered by a Healthcare Professional.

PBS information: Not listed on the PBS for the treatment of generalised myasthenia gravis

Please review the full Product Information before prescribing RYSTIGGO^®. The full Product Information is available from UCB Australia here.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.